TITLE

Effect of Coadministration of Neurovite and Lamivudine on the Histomorphology of the Cerebellum of Wistar Rats

AUTHOR(S)
Peter, A. I.; Ekong, M. B.; Davies, K.; Azu, O. O.; Bassey, R. B.; Ugwu, L. O.; Umoh, I. U.
PUB. DATE
January 2014
SOURCE
ISRN Otolaryngology;2014, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Introduction. Lamivudine is a nucleoside reverse transcriptase inhibitor antiretroviral agent used in the treatment of human immunodeficiency virus type 1 infection. This study was to investigate the effects of coadministration of neurovite and lamivudine on the histomorphology of the cerebellum of Wistar rats. Materials and Methods. TwentyWistar rats were divided equally into four groups. Group A animals were the control treated with distilled water. Groups B, C, and D animals were treated, respectively, with therapeutic dose of lamivudine (4.28 mg/kg), a combination of lamivudine (4.28 mg/kg) and neurovite (7.05 mg/kg), and neurovite (7.05 mg/kg) alone, daily. The rats were sacrificed using chloroform inhalation, processed, and stained using H&E method. Results. There was severe cellular degeneration with dystrophic changes, vacuolization in the molecular and granular layers, and aggregation of swollen Purkinje cells in group B animals compared with group C animals which showed only slight cellular dystrophy and inflammation. The mean cellular population was significantly (P < 0.05) higher in the treatment groups compared with the control. Conclusion. There was amelioration of damage of the cerebellumin the animals treated with neurovite and lamivudine combination compared to animals treated with only lamivudine. Therefore, there is need to give neurovite to patients on lamivudine therapy.
ACCESSION #
100567817

 

Related Articles

  • Zidovudine/Lamivudine for HIV-1 Infection Contributes to Limb Fat Loss. van Vonderen, Marit G. A.; van Agtmael, Michiel A.; Hassink, Elly A. M.; Milinkovic, Ana; Brinkman, Kees; Geerlings, Suzanne E.; Ristola, Matti; van Eeden, Arne; Danner, Sven A.; Reiss, Peter // PLoS ONE;2009, Vol. 4 Issue 5, p1 

    Background: Lipoatrophy is known to be associated with stavudine as part of the treatment for HIV infection, but it is less clear if this serious side effect is also related to other nucleoside reverse transcriptase inhibitors like zidovudine. We aimed to determine whether zidovudine-sparing...

  • Lamivudine monotherapy as a holding regimen in the era of antiretroviral treatment resistance. Meyer, J. C.; Schellack, N. B. // South African Pharmaceutical Journal;2015, Vol. 82 Issue 9, p43 

    Limited treatment options are available for HIV-infected paediatric patients that are virologically failing combination antiretroviral treatment (cART). This paper describes the use of lamivudine monotherapy (LM) as a holding strategy for the short-term treatment of specific multi-drug resistant...

  • Azvudine, A Novel Nucleoside Reverse Transcriptase Inhibitor Showed Good Drug Combination Features and Better Inhibition on Drug-Resistant Strains than Lamivudine In Vitro. Wang, Rui-Rui; Yang, Qing-Hua; Luo, Rong-Hua; Peng, You-Mei; Dai, Shao-Xing; Zhang, Xing-Jie; Chen, Huan; Cui, Xue-Qing; Liu, Ya-Juan; Huang, Jing-Fei; Chang, Jun-Biao; Zheng, Yong-Tang // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Azvudine is a novel nucleoside reverse transcriptase inhibitor with antiviral activity on human immunodeficiency virus, hepatitis B virus and hepatitis C virus. Here we reported the in vitro activity of azvudine against HIV-1 and HIV-2 when used alone or in combination with other antiretroviral...

  • CONTROLLED AND SUSTAINED RELEASE APPROACHES IN DEVELOPING SUITABLE DOSAGE FORMS FOR THE ANTIRETROVIRAL DRUG LAMIVUDINE. Vamshi Alla, Krishna; Praveen Kumar, Gannu; Cheruku, Vishvasa; Jannu, Anand; Kumari Bairi, Chaitanya // International Journal of Pharmaceutical Sciences Review & Resear;May/Jun2011, Vol. 8 Issue 1, p21 

    Lamivudine is a Nucleoside Reverse Transcriptase Inhibitor (NRTI), licensed for the treatment of HIV, and chronic Hepatitis B. The pharmacokinetic data of Lamivudine shows that, frequent administration for a prolonged period of time (lifelong in AIDS and for one year in hepatitis patients) is...

  • Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. Wan-Lin Yang; Kouyos, Roger D.; Scherrer, Alexandra U.; Böni, Jürg; Shah, Cyril; Yerly, Sabine; Klimkait, Thomas; Aubert, Vincent; Hirzel, Cédric; Battegay, Manuel; Cavassini, Matthias; Bernasconi, Enos; Vernazza, Pietro; Held, Leonhard; Ledergerber, Bruno; Günthard, Huldrych F. // Journal of Antimicrobial Chemotherapy (JAC);Dec2015, Vol. 70 Issue 12, p3323 

    Background: The most recommended NRTI combinations as first-line antiretroviral treatment for HIV-1 infection in resource-rich settings are tenofovir/emtricitabine, abacavir/lamivudine, tenofovir/lamivudine and zidovudine/lamivudine. Efficacy studies of these combinations also considering pill...

  • Positioning of HIV-protease inhibitors in clinical practice. Andreoni, M.; Perno, C. F. // European Review for Medical & Pharmacological Sciences;2012, Vol. 16 Issue 1, p10 

    The availability of more than 20 drugs for the treatment of HIV infection, and the success of the current antiretroviral regimens, should not overlook the difficulty of longterm maintaining the control of viral replication. The therapy needs to be continued for decades, if not for lifetime, and...

  • The current state of HIV therapy. Benzer, Jessica A.; Riley, Ted K.; Lee, Jean C. // Formulary;Jul2013, Vol. 48 Issue 7, p213 

    Incidence of human immunodeficiency virus (HIV) has decreased dramatically since its emergence in the early 1980s, but it remains a worldwide epidemic. There is a reduction in newly diagnosed patients, but prevalence is increasing due to a longer life expectancy, which is attributed in part to...

  • Pharmacological and clinical evidence of nevirapine immediate-and extended-release formulations. Ena, Javier; Amador, Concepción; Benito, Conxa; Pasquau, Francisco // HIV/AIDS - Research & Palliative Care;2012, Vol. 4, p169 

    We reviewed the current information available on nevirapine immediate- and extended-release formulations and its role in single-dose and combination antiretroviral therapy. Nevirapine was approved in 1996 and was the first non-nucleoside reverse-transcriptase inhibitor available for the...

  • Induction with Lopinavir-Based Treatment Followed by Switch to Nevirapine-Based Regimen versus Non-Nucleoside Reverse Transcriptase Inhibitors-Based Treatment for First Line Antiretroviral Therapy in HIV Infected Children Three Years and Older. Alvarez-Uria, Gerardo; Pakam, Raghavakalyan; Naik, Praveen Kumar; Midde, Manoranjan // PLoS ONE;Sep2014, Vol. 9 Issue 9, p1 

    Background: The World Health Organization recommends non-nucleoside reverse transcriptase inhibitors (NNRTIs)-based antiretroviral therapy (ART) for children three years and older. In younger children, starting ART with lopinavir boosted with ritonavir (LPVr) results in lower risk of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics